Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today ...

For patients with metastatic uveal melanoma, what are the treatment options? Marlana M. Orloff, M.D.: Metastatic uveal melanoma is unique in that when patients recur, close to 90% or more recur in ...

IDEAYA Biosciences recently completed full enrollment of 435 patients in its registration-enabling Phase 2/3 OptimUM-02 trial testing oral PKC inhibitor darovasertib plus Pfizer’s crizotinib in ...

This collaboration broadens access to advanced monitoring solutions for uveal melanoma patients in the United States, helping to address the needs of a largely underserved patient population. By ...

Here is a breakdown of some of the important information surrounding uveal melanoma, an extremely rare form of cancer. Uveal melanoma is a rare form of eye cancer that many patients may not be aware ...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its ...

MADRID — The positive effect of the bispecific fusion protein tebentafusp on the overall survival of patients with uveal melanoma in the IMCgp100-202 study lasted through at least 36 months of ...

ROCHESTER, Minnesota — Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better ...

Researchers have identified a new drug combination that is effective against metastatic uveal melanoma cells in preclinical studies. Uveal melanoma is a very aggressive type of melanoma that affects ...

Uveal melanoma is the most common primary malignancy of the eye and frequently leads to metastatic death. Until the mid-20th Century, the only treatment for uveal melanoma was enucleation. Since then, ...